Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Gefitinib-induced disseminated intravascular coagulation in a patient with non-small cell lung cancer.

Yuan GJ, Ke QH, Xu XM, Yang JY, Su XY.

Chin Med J (Engl). 2010 Feb 20;123(4):505-6. No abstract available.

PMID:
20193495
2.

APL during gefitinib treatment for non-small-cell lung cancer.

Uchida A, Matsuo K, Tanimoto M.

N Engl J Med. 2005 Feb 24;352(8):843. No abstract available.

3.

Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution.

Matsuo K, Kiura K, Tabata M, Uchida A, Hotta K, Niiya D, Kubonishi S, Ogino A, Fujiwara Y, Nakajima H, Shinagawa K, Ishimaru F, Ueoka H, Tanimoto M.

Am J Hematol. 2006 May;81(5):349-54.

4.

Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.

Chang GC, Yang TY, Chen KC, Yin MC, Wang RC, Lin YC.

J Clin Oncol. 2004 Nov 15;22(22):4646-8. No abstract available.

PMID:
15542815
5.

Acute gefitinib-induced pneumonitis.

Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y.

Int J Clin Oncol. 2004 Oct;9(5):406-9.

PMID:
15549594
6.

Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis.

Nagaria NC, Cogswell J, Choe JK, Kasimis B.

J Clin Oncol. 2005 Apr 1;23(10):2423-4. No abstract available.

PMID:
15800334
7.

Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer.

Wang MZ, Li LY, Wang SL, Zhang XT, Zhong W, Zhang L.

Chin Med J (Engl). 2006 Jan 5;119(1):63-8. No abstract available.

PMID:
16454984
8.

Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study.

Hotta K, Inoue A, Kiura K, Ueoka H, Nukiwa T, Tanimoto M.

Lung Cancer. 2005 Dec;50(3):413-5. Epub 2005 Sep 8. No abstract available.

PMID:
16154232
9.

Severe purpuric xerotic dermatitis associated with gefitinib therapy.

Sheen YS, Hsiao CH, Chu CY.

Arch Dermatol. 2008 Feb;144(2):269-70. doi: 10.1001/archdermatol.2007.53. No abstract available.

PMID:
18283195
10.

[Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib].

Zhang PL, Chen L.

Zhonghua Zhong Liu Za Zhi. 2007 Aug;29(8):635-6. Chinese. No abstract available.

PMID:
18210890
11.

Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature.

Voulgaris E, Pentheroudakis G, Vassou A, Pavlidis N.

Lung Cancer. 2009 May;64(2):247-9. doi: 10.1016/j.lungcan.2008.10.027. Epub 2008 Dec 12.

PMID:
19070399
12.

Gefitinib. Still no convincing results in non-small cell lung cancer.

[No authors listed]

Prescrire Int. 2010 Jun;19(107):113. No abstract available.

PMID:
20738034
13.

Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.

Tsuboi M, Kato H, Nagai K, Tsuchiya R, Wada H, Tada H, Ichinose Y, Fukuoka M, Jiang H.

Anticancer Drugs. 2005 Nov;16(10):1123-8.

PMID:
16222155
14.
15.

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.

Yin YM, Geng YT, Shao YF, Hu XL, Li W, Shu YQ, Wang ZX.

J Exp Clin Cancer Res. 2010 Sep 15;29:126. doi: 10.1186/1756-9966-29-126.

16.

[Erlotinib. A new option for non-small cell lung cancer].

Polk B.

Med Monatsschr Pharm. 2006 Jan;29(1):4-6. Review. German. No abstract available.

PMID:
16463547
17.

Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases.

Rossi A, Maione P, Del Gaizo F, Guerriero C, Castaldo V, Gridelli C.

Lung Cancer. 2005 Mar;47(3):421-3.

PMID:
15713526
18.

Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program.

Gridelli C, Rossi A, Maione P, Guerriero C, Airoma G, Colantuoni G, Barzelloni ML.

Anticancer Res. 2004 May-Jun;24(3b):1873-7.

19.

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.

Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N.

Lung Cancer. 2004 Jul;45(1):93-104.

PMID:
15196739
20.

Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group.

Hotta K, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Moritaka T, Shibayama T, Matsuo K, Kato K, Kanehiro A, Tanimoto Y, Matsuo K, Ueoka H, Tanimoto M.

Cancer J. 2005 Sep-Oct;11(5):417-24.

PMID:
16259873

Supplemental Content

Support Center